epoetin-alfa and Glaucoma

epoetin-alfa has been researched along with Glaucoma* in 2 studies

Reviews

2 review(s) available for epoetin-alfa and Glaucoma

ArticleYear
Erythropoietin in Glaucoma: From Mechanism to Therapy.
    International journal of molecular sciences, 2023, Feb-03, Volume: 24, Issue:3

    Glaucoma can cause irreversible vision loss and is the second leading cause of blindness worldwide. The disease mechanism is complex and various factors have been implicated in its pathogenesis, including ischemia, excessive oxidative stress, neurotropic factor deprivation, and neuron excitotoxicity. Erythropoietin (EPO) is a hormone that induces erythropoiesis in response to hypoxia. However, studies have shown that EPO also has neuroprotective effects and may be useful for rescuing apoptotic retinal ganglion cells in glaucoma. This article explores the relationship between EPO and glaucoma and summarizes preclinical experiments that have used EPO to treat glaucoma, with an aim to provide a different perspective from the current view that glaucoma is incurable.

    Topics: Epoetin Alfa; Erythropoietin; Glaucoma; Humans; Neuroprotective Agents; Receptors, Erythropoietin; Retinal Ganglion Cells

2023
The Latest Evidence of Erythropoietin in the Treatment of Glaucoma.
    International journal of molecular sciences, 2022, Dec-16, Volume: 23, Issue:24

    Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell production, EPO has pluripotent potential, such as for cognition improvement, neurogenesis, and anti-fibrotic, anti-apoptotic, anti-oxidative, and anti-inflammatory effects. In human retinal tissues, EPO receptors (EPORs) are expressed in the photoreceptor cells, retinal pigment epithelium, and retinal ganglion cell layer. Studies have suggested its potential therapeutic effects in many neurodegenerative diseases, including glaucoma. In this review, we discuss the correlation between glaucoma and EPO, physiology and potential neuroprotective function of the EPO/EPOR system, and latest evidence for the treatment of glaucoma with EPO.

    Topics: Epoetin Alfa; Erythropoietin; Glaucoma; Humans; Receptors, Erythropoietin; Retinal Ganglion Cells

2022